openPR Logo
Press release

Alzheimer's Disease Market Poised for Growth by 2032, Projects DelveInsight | Eisai, Biogen, Changchun Huayang High-tech Co., Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly,

04-12-2024 12:22 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

Alzheimer's Disease Market

Alzheimer's Disease Market

(Albany, USA) DelveInsight's "Alzheimer's Disease Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Alzheimer's Disease, historical and forecasted epidemiology as well as the Alzheimer's Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Alzheimer's Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Alzheimer's Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Alzheimer's Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Alzheimer's Disease market.

Request for a Free Sample Report @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some facts of the Alzheimer's Disease Market Report are:
• According to DelveInsight, Alzheimer's Disease market size is expected to grow at a decent CAGR by 2032.
• Leading Alzheimer's Disease companies working in the market are Eisai, Biogen, Changchun Huayang High-tech Co. Ltd., Hoffmann-La Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Prilenia Therapeutics, Denali Therapeutics Inc., Stemedica Cell Technologies, Inc. and many others.
• As per Alzheimer's Disease pipeline analysis, there are currently 150+ companies and 150+ pipeline drugs depicting a pretty fertile picture of the market in the cooking years.
• Key Alzheimer's Disease Therapies expected to launch in the market are Lecanemab (BAN2401), Tricaprilin, Aducanumab (BIIB037), Gantenerumab (RG1450, RO4909832), Brexpiprazole (REXULTI / RXULTI), AL002, ALZT-OP1, Brilaroxazine (RP5063), BIIB076, and others.
• In 2023, the U.S. Food and Drug Administration (FDA) approved lecanemab (Leqembi) for people with mild Alzheimer's disease and mild cognitive impairment due to Alzheimer's disease. A phase 3 clinical trial found that the medicine slowed cognitive decline in people with early Alzheimer's disease.
• Aducanumab was the first therapy to demonstrate that removing beta-amyloid, one of the hallmarks of Alzheimer's disease, from the brain reduces cognitive and functional decline in people living with early Alzheimer's.
• In 2023, Eli Lilly announced it had met the primary endpoint in a Phase III study of donanemab, having slowed clinical decline in patients with mild to moderate Alzheimer's disease (AD) by 35% compared to placebo. As against previously approved anti-amyloid therapies like lecanemab marketed as Leqembi, and Biogen's aducanumab marketed as Aduhelm, donanemab showed higher levels of efficacy indicating another success for those researching Alzheimer's disease.

Alzheimer's disease Overview
Alzheimer's disease is a progressive neurological disorder characterized by memory loss, cognitive decline, and changes in behaviour. It is the most common form of dementia, affecting millions of people worldwide. The disease gradually damages brain cells, leading to the impairment of memory, thinking, and communication skills. As the condition progresses, individuals may struggle with daily tasks and experience personality changes. There is currently no cure for Alzheimer's disease, but various treatments and therapies can help manage symptoms and improve quality of life. Ongoing research aims to better understand the disease's causes and develop more effective interventions.

Learn more about Alzheimer's Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Market
The Alzheimer's Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Alzheimer's Disease market trends by analyzing the impact of current Alzheimer's Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Alzheimer's Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Alzheimer's Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Alzheimer's Disease market in 7MM is expected to witness a major change in the study period 2019-2032.

Alzheimer's Disease Epidemiology
The Alzheimer's Disease epidemiology section provides insights into the historical and current Alzheimer's Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Alzheimer's Disease market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Alzheimer's Disease Epidemiology @ https://www.delveinsight.com/report-store/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Drugs Uptake
This section focuses on the uptake rate of the potential Alzheimer's Disease drugs recently launched in the Alzheimer's Disease market or expected to be launched in 2019-2032. The analysis covers the Alzheimer's Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Alzheimer's Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Alzheimer's Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Alzheimer's Disease Pipeline Development Activities
The Alzheimer's Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Alzheimer's Disease key players involved in developing targeted therapeutics.
• Lecanemab (BAN2401): Eisai/ BioArctic AB (Sweden)
• Tricaprilin: Cerecin
• Aducanumab (BIIB037): Biogen
• Gantenerumab (RG1450, RO4909832): Chugai Pharmaceuticals (Hoffmann-La Roche)
• Brexpiprazole (REXULTI / RXULTI): Otsuka Pharmaceutical
• AL002: Alector
• ALZT-OP1: AZ Therapies
• Brilaroxazine (RP5063): Reviva Pharmaceuticals
• BIIB076: Neurimmune

Request for a sample report to understand more about the Alzheimer's Disease pipeline development activities @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Therapeutics Assessment
Major key companies are working proactively in the Alzheimer's Disease Therapeutics market to develop novel therapies which will drive the Alzheimer's Disease treatment markets in the upcoming years are Eisai/ BioArctic AB, Biogen, Otsuka Pharmaceutical, Hoffmann-La Roche/Chugai Pharmaceuticals, Alector, AbbVie, Reviva Pharmaceutical, AZ Therapies, Cerecin, Anavex Life Sciences Corp., Neurimmune, and others.

Learn more about the emerging Alzheimer's Disease therapies & key companies @ https://www.delveinsight.com/sample-request/alzheimers-disease-ad-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Alzheimer's Disease Report Key Insight
1. Alzheimer's Disease Patient Population
2. Alzheimer's Disease Market Size and Trends
3. Key Cross Competition in the Alzheimer's Disease Market
4. Alzheimer's Disease Market Dynamics (Key Drivers and Barriers)
5. Alzheimer's Disease Market Opportunities
6. Alzheimer's Disease Therapeutic Approaches
7. Alzheimer's Disease Pipeline Analysis
8. Alzheimer's Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Alzheimer's Disease Market

Table of Contents
1. Key Insights
2. Executive Summary
3. Alzheimer's Disease Competitive Intelligence Analysis
4. Alzheimer's Disease Market Overview at a Glance
5. Alzheimer's Disease Disease Background and Overview
6. Alzheimer's Disease Patient Journey
7. Alzheimer's Disease Epidemiology and Patient Population
8. Alzheimer's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Alzheimer's Disease Unmet Needs
10. Key Endpoints of Alzheimer's Disease Treatment
11. Alzheimer's Disease Marketed Products
12. Alzheimer's Disease Emerging Therapies
13. Alzheimer's Disease Seven Major Market Analysis
14. Attribute Analysis
15. Alzheimer's Disease Market Outlook (7 major markets)
16. Alzheimer's Disease Access and Reimbursement Overview
17. KOL Views on the Alzheimer's Disease Market
18. Alzheimer's Disease Market Drivers
19. Alzheimer's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer

Trending Reports:
• Asphyxia Market: https://www.delveinsight.com/report-store/asphyxia-market
• Asherman's Syndrome Market: https://www.delveinsight.com/report-store/ashermans-syndrome-market
• Acute Agitation And Aggression Market: https://www.delveinsight.com/report-store/acute-agitation-and-aggression-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Chronic pruritus market: https://www.delveinsight.com/report-store/chronic-pruritus-market
• Hiatal hernia market: https://www.delveinsight.com/report-store/hiatal-hernia-market
• Pediatric obesity market: https://www.delveinsight.com/report-store/pediatric-obesity-market
• Acral Lentiginous Melanoma Market: https://www.delveinsight.com/report-store/acral-lentiginous-melanoma-market
• Anaphylaxis Market: https://www.delveinsight.com/report-store/anaphylaxis-market
• Aortic Stenosis Market: https://www.delveinsight.com/report-store/aortic-stenosis-market
• Binge Eating Disorder Market: https://www.delveinsight.com/report-store/binge-eating-disorders-market
• Chronic Myelogenous Leukemia Market: https://www.delveinsight.com/report-store/chronic-myelogenous-leukemia-market
• Familial Primary Pulmonary Hypertension Market: https://www.delveinsight.com/report-store/familial-primary-pulmonary-hypertension-market
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Meningioma Market: https://www.delveinsight.com/report-store/meningioma-market
• Optic Neuritis Market: https://www.delveinsight.com/report-store/optic-neuritis-market
• Partial Seizure Market: https://www.delveinsight.com/report-store/partial-seizure-market
• Progressive Multifocal Leukoencephalopathy Market: https://www.delveinsight.com/report-store/progressive-multifocal-leukoencephalopathy-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Cluster Headache Market: https://www.delveinsight.com/report-store/cluster-headache-market
• Minimal Residual Disease Market: https://www.delveinsight.com/report-store/minimal-residual-disease-market
• Achondroplasia Market: https://www.delveinsight.com/report-store/achondroplasia-market
• Actinic Keratosis Market: https://www.delveinsight.com/report-store/actinic-keratosis-market
• Aesthetic Implants Market: https://www.delveinsight.com/report-store/aesthetic-implants-market
• Alzheimer Disease Market: https://www.delveinsight.com/report-store/alzheimers-disease-ad-market
• Angioedema Market: https://www.delveinsight.com/report-store/angioedema-market
• Blood Gas And Electrolyte Analyzers Market: https://www.delveinsight.com/report-store/blood-gas-and-electrolyte-analyzers-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Calciphylaxis Market: https://www.delveinsight.com/report-store/calciphylaxis-pipeline-insight
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Chemotherapy Induced Thrombocytopenia Market: https://www.delveinsight.com/report-store/chemotherapy-induced-thrombocytopenia-market-size
• Chronic Lymphocytic Leukemia Cll Market: https://www.delveinsight.com/report-store/chronic-lymphocytic-leukemia-cll-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Eczema Market: https://www.delveinsight.com/report-store/eczema-market
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Ventricular Hypertrophy Market: https://www.delveinsight.com/report-store/hypertrophic-cardiomyopathy-pipeline-insight
• Cerebral Aneurysm Market: https://www.delveinsight.com/report-store/intracranial-aneurysms-market-insight
• Lewy Body Dementia Market: https://www.delveinsight.com/report-store/lewy-body-dementia-market
• Multiple Myeloma Market: https://www.delveinsight.com/report-store/multiple-myeloma-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/negative-pressure-wound-therapy-systems-market
• Neuroblastoma Market: https://www.delveinsight.com/report-store/neuroblastoma-market
• Neurostimulation Devices Market: https://www.delveinsight.com/report-store/neurostimulation-devices-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Nsclc Market: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Osteoarthritis Market: https://www.delveinsight.com/report-store/osteoarthritis-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment
• Pruritus Market: https://www.delveinsight.com/report-store/pruritus-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Chronic Lymphocytic Leukemia Market: https://www.delveinsight.com/report-store/relapsed-chronic-lymphocytic-leukemia-cll-market
• Ventilator Market: https://www.delveinsight.com/report-store/ventilators-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Alzheimer's Disease Market Poised for Growth by 2032, Projects DelveInsight | Eisai, Biogen, Changchun Huayang High-tech Co., Roche, vTv Therapeutics, AZTherapies, Cerecin, Neurotrope, Lyndra, AC Immune, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, here

News-ID: 3461748 • Views:

More Releases from DelveInsight Business Research

Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibrillation Space by DelveInsight
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals. Objective of the Case Study The
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestones, Therapies in Development, Mechanisms of Action, and Routes of Administration - By DelveInsight
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics. According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Rising Cancer Burden and Technological Advancements, states DelveInsight
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies. Biopsy devices play a crucial role in disease diagnosis by
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven by Rising Surgical Procedures, Technological Advancements, and Growing Adoption of Minimally Invasive Techniques, States DelveInsight
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide. DelveInsight's General Surgery Devices Market Report 2032 provides

All 5 Releases


More Releases for Alzheimer

Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion. Data Bridge
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as